TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
An Oct. 21 psychiatry roundup highlighted a small sham-controlled trial in which one 10-minute transcranial ultrasound session was linked to a modest reduction in delusion scores. It also reported a study identifying a circadian pattern in some severe, recurrent depression and concerns about protections for people with eating disorders as GLP-1 drugs become more widely used. The findings do not establish ultrasound as a treatment or show how GLP-1 use affects eating-disorder outcomes.
A psychiatry news roundup published Oct. 21 highlighted three developments: a small trial reporting a modest reduction in delusion scores after transcranial ultrasound, a study identifying a circadian subtype among some adults with severe recurrent depression, and concerns about eating-disorder safeguards as GLP-1 drugs gain use. The reports point to research and patient-protection questions, but do not establish ultrasound as an effective schizophrenia treatment or quantify GLP-1-related eating-disorder harms.
The roundup, published by MedPage Today, said a sham-controlled pilot trial found that a single 10-minute transcranial ultrasound session led to a modest but statistically significant decrease in delusion scores among people with schizophrenia. The report cited a study in npj Acoustics. A pilot result can support further research, but the brief summary does not provide the number of participants, how long any change lasted, or whether other symptoms improved.
A cross-sectional study published in the British Journal of Psychiatry found that roughly one-quarter of adults with severe, recurrent depressive disorders had what researchers described as a “circadian subtype.” The report characterized it by disrupted 24-hour sleep-wake cycles. Because the study was cross-sectional, the roundup does not establish whether circadian disruption causes depression, results from it, or how the proposed subtype might guide care.
On eating disorders, the roundup cited a New York Times report saying that few safeguards exist to protect patients amid the growth in GLP-1 drug use. It also summarized results from the CDC’s 2025 Youth Risk Behavior Survey: 40.5% of high school students reported binge eating on at least one day in the previous 30 days, while 17.2% reported three or more days. Those survey figures describe reported behavior among students; they do not establish an eating-disorder diagnosis or a link to GLP-1 medicines.
Early Findings, Open Patient-Safety Questions
The three items matter for different reasons. The ultrasound result offers a preliminary signal that a noninvasive brain-stimulation approach may affect delusions, a symptom that can be difficult to treat. But a single pilot session is not evidence of lasting benefit, and readers should not interpret the result as an established therapy. Larger studies would need to test durability, safety, and which patients, if any, benefit.
The reported circadian pattern may help researchers examine how sleep-wake rhythms relate to severe recurrent depression. At present, the roundup describes a study classification, not a validated diagnostic test or a treatment recommendation. The GLP-1 discussion raises a more immediate policy and care question: whether people with eating disorders receive appropriate screening and support as these medicines are used. The available summary flags a safeguard gap but does not detail its scope or measure harm.
transcranial ultrasound device for mental health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Three Findings in a Psychiatry Roundup
The source is a short Oct. 21, 2026 MedPage Today roundup, not a single study or coordinated research project. It brings together reports from separate publications, including npj Acoustics, the British Journal of Psychiatry, CDC survey findings and a New York Times article. The items therefore have different methods and evidence limits: a sham-controlled pilot trial, a cross-sectional study, a national youth survey and reporting on patient protections.
The CDC figures provide a population snapshot for the prior 30 days, while the other two research findings address different questions in clinical psychiatry. The roundup also listed unrelated developments, but the ultrasound, depression-subtype and GLP-1/eating-disorder items form the central set summarized here. No shared causal connection among them was reported.
“A single, 10-minute transcranial ultrasound session led to a modest but significant drop in delusion scores among people with schizophrenia in a sham-controlled pilot trial.”
— MedPage Today roundup, summarizing the ultrasound trial
light therapy lamp for seasonal depression
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial Limits and Missing Safeguard Details
The supplied roundup does not give the ultrasound trial’s sample size, follow-up period, effect size or adverse-event details. It is therefore unclear how durable the change in delusion scores was or whether it would be clinically meaningful beyond the pilot. The depression study summary likewise does not specify its sample size, criteria for the circadian subtype, or whether researchers tested outcomes over time.
For GLP-1s and eating disorders, the source does not identify which safeguards are missing, how many patients are affected, or whether the concern relates to prescribing, screening, monitoring or access to specialist support. The CDC survey does not report a causal relationship between GLP-1 drugs and binge eating. These limits mean the three items should be read as separate developments, not evidence of a shared trend or cause.
As an affiliate, we earn on qualifying purchases.
What Further Reporting Must Establish
The next evidence to watch for is fuller publication of the ultrasound and circadian-depression research, including methods, participant numbers, follow-up and limitations. Further controlled studies would be needed to determine whether ultrasound produces sustained symptom changes and whether the proposed depression subtype has practical value for diagnosis or care.
On eating-disorder protections, further reporting and guidance would need to clarify what safeguards are currently in place and where gaps occur for people considering or using GLP-1 medicines. The roundup does not announce a policy change, new clinical guideline or scheduled milestone. Until more detail is available, the confirmed development is the publication of these findings and concerns—not a change in standard treatment or a proven drug-related eating-disorder effect.
sleep cycle monitor for circadian rhythm
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does the ultrasound study show that ultrasound treats schizophrenia?
No. The roundup describes a sham-controlled pilot trial in which one session was associated with a modest reduction in delusion scores. It does not establish lasting benefit or an approved treatment.
What does “circadian subtype” mean in this report?
The roundup uses the term for a reported pattern of severe, recurrent depression associated with disrupted 24-hour sleep-wake cycles. The summary does not establish a new diagnosis or explain how the label would change care.
Do the CDC figures show that GLP-1 drugs cause binge eating?
No. The CDC figures describe students’ self-reported binge-eating frequency over the previous 30 days. The roundup reports no causal link between those figures and GLP-1 medicines.
What is unclear about safeguards for people with eating disorders?
The cited report says safeguards are limited, but the supplied summary does not specify which protections are missing or measure the scale of the problem. Details about screening, prescribing and follow-up are not provided.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
